News und Analysen
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration with BioNTech SE (Nasdaq: BNTX) to develop and commercialize a tissue-based companion diagnostic –
QIAGEN arbeitet mit BioNTech an der Entwicklung eines Begleitdiagnostikums zur Identifizierung von HPV-assoziierten Plattenepithelkarzinomen in der Kopf-Hals-Region
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, im Rahmen einer strategischen Zusammenarbeit gemeinsam mit der BioNTech SE (Nasdaq: BNTX) ein gewebebasiertes
ProvideGx® Partners with Fresenius Kabi to Help Stabilize Supply of Heparin, a Vital Medication
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Fresenius Kabi to supply pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers
QIAGEN führt NeuMoDx-Multiplex-Test zur Vervollständigung des SARS-CoV-2-Testportfolios in Europa und weiteren Märkten ein
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Einführung des NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Tests bekannt gegeben, mit dem medizinische Fachkräfte häufige saisonal
QIAGEN Launches NeuMoDx Multiplex Test to Complete Range of SARS-CoV-2 Testing Solutions in Europe and Other Markets
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the European launch of the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test that will help healthcare professionals quickly
Premier and 34 Leading Health Systems Partner with DeRoyal to Expand Domestic Production of Isolation Gowns
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, and 34 member health systems partnered with DeRoyal Industries Inc., a global medical manufacturer, to create a new joint
Prüfungsausschuss beschließt Erstattung medizinischer Leistungen für Behandlung mit Tumor-Therapie-Feldern in Deutschland
Wie Novocure (NASDAQ: NVCR) heute mitteilte, haben Vertreter der Bundesärztekammer und der Bundesvereinigung der gesetzlichen Krankenkassen die Erstattung ärztlicher Leistungen bei Indikation
Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency
Regulatory News:
Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
Charles River and PathoQuest Strengthen Strategic Partnership
PathoQuest SAS, a genomic expert company dedicated to quality control testing of biologics, and its strategic partner Charles River Laboratories International, Inc. (NYSE: CRL), announced today
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination
QIAGEN führt mobilen digitalen SARS-CoV-2-Antigentest mit hoher Genauigkeit und einer Analysekapazität von mehr als 30 Proben pro Stunde ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat in den USA mit der Vermarktung eines mobilen digitalen Tests für Labore begonnen, mit dem ein Nachweis von SARS-CoV-2-Antigenen bei Menschen
QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has started commercialization of a portable digital test in the United States that can be used by laboratories to detect SARS-CoV-2 antigens in
Novocure Receives CE Mark for NovoTTF-100L™ System
Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that it has received the CE Mark for the NovoTTF-100L
ICON Releases First Environmental, Social and Governance Report
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
LivaNova to Present at the Stifel 2020 Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare
Novocure Announces Agenda for Virtual Research and Development Day
Novocure (NASDAQ: NVCR) today announced the agenda for the company’s virtual Research and Development Day for analysts and investors from 7:30 a.m. to 9:30 a.m. EST on Thursday, November 12, 2020
Charles River Laboratories to Present at Upcoming Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:
-
Credit Suisse 29th Annual Virtual
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the
Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported data from its
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship Banks
Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201108005065/en/
Vifor Pharma and Angion Biomedica Corp. (Angion)
Chemed Corporation Declares Quarterly Dividend of 34 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 34-cents per share on the Company’s capital stock, payable on December 7, 2020
AMN Healthcare Announces Third Quarter 2020 Results
AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its third quarter 2020 financial
Xencor Reports Third Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial